Article in American journal of physiology. Renal physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Yuting ZengDepartment of Chemistry, University of Washington, Seattle, Washington, United States.ORCID 0000-0002-3751-2013
R Allen SchweickartDepartment of Heart, Blood and Kidney Research, Cleveland Clinic Research, Cleveland Clinic Foundation, Cleveland, Ohio, United States.ORCID 0000-0001-9126-7883
Jana ShararaDepartment of Heart, Blood and Kidney Research, Cleveland Clinic Research, Cleveland Clinic Foundation, Cleveland, Ohio, United States.ORCID 0000-0002-9766-326X
Joseph C MaggioreDepartment of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.ORCID 0000-0001-7586-4493
Carol J LoretzDivision of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, United States.
Neil A HukriedeDepartment of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.ORCID 0000-0002-9655-9030
Jeffery W PippinDivision of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, United States.ORCID 0009-0000-1629-1728
Ashleigh B ThebergeDepartment of Chemistry, University of Washington, Seattle, Washington, United States.ORCID 0000-0002-3394-1435
Oliver WesselyDepartment of Heart, Blood and Kidney Research, Cleveland Clinic Research, Cleveland Clinic Foundation, Cleveland, Ohio, United States.ORCID 0000-0001-6440-7975
Stuart J ShanklandDivision of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, United States.ORCID 0000-0002-4616-8330
Funding
Cellular Approaches to Tissue Engineering/RegenerationT32EB001026 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUNCAN, ANDREW W, MONGA, SATDARSHAN SINGH · 2003 to 2024
$5.5M
Juxta-glomerular cells serve as glomerular epithelial cell progenitors in glomerular diseaseR01DK097598 · NIDDK · UNIVERSITY OF WASHINGTON · PI SHANKLAND, STUART JAMES, WESSELY, OLIVER · 2014 to 2022
$5.2M
Resource Development CoreU54DK137329 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Gerard L Apodaca · 2023 to 2026
$4.8M
Theberge Admin Supp Undergraduate Summer Research ExperiencesR35GM128648 · NIGMS · UNIVERSITY OF WASHINGTON · PI Ashleigh Brooks Theberge · 2018 to 2026
$4.7M
Cell specific delivery of novel therapies to enhance glomerular regeneration and repairUC2DK126006 · NIDDK · UNIVERSITY OF WASHINGTON · PI SHANKLAND, STUART JAMES · 2020 to 2024
$4.0M
Autocrine and paracrine podocyte signals decrease glomerular function/health in aged kidneysR01DK128204 · NIDDK · UNIVERSITY OF WASHINGTON · PI Stuart James Shankland, Oliver Wessely · 2022 to 2026
$3.7M
CELL CYCLE PROTEINS AND GLOMERULAR APOPTOSISR01DK056799 · NIDDK · UNIVERSITY OF WASHINGTON · PI SHANKLAND, STUART JAMES · 2000 to 2014
$3.6M
Therapeutic Optimization of Productive Repair After Acute Kidney InjuryUC2DK126122 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DAVIDSON, ALAN, DE CAESTECKER, MARK P. · 2020 to 2024
$3.2M
American Society of Nephrology (ASN) KidneyCure Predoctoral FellowshipHHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1R01DK097598-01A1HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5R01DK056799HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5UC2DK126006HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5UC2DK126122HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM128648NIBIB NIH HHS T32 EB001026NIDDK NIH HHS R01 DK056799NIDDK NIH HHS R01 DK097598NIDDK NIH HHS R01 DK128204NIDDK NIH HHS U54 DK137329NIDDK NIH HHS UC2 DK126006NIDDK NIH HHS UC2 DK126122NIGMS NIH HHS R35 GM128648U.S. Department of Defense (DOD) HT9425-23-1-0480U.S. Department of Defense (DOD) PR180585/PR180585P1
6 · The paper itself
Abstract
Although injury in glomerular disease might only damage a subset of podocytes in any given glomerulus, the response of the healthy neighboring podocytes to the injured podocytes oftentimes determines the course of the disease. To investigate this relationship, we designed a dual-chamber open microfluidic coculture device to specifically examine paracrine signaling from podocytes undergoing targeted injury by either adriamycin, puromycin aminonucleoside, or a cytopathic antipodocyte antibody to healthy podocytes. Global transcriptomic analysis measured by RNA sequencing revealed shared and unique pathways between the three forms of targeted injury, with temporal differences in the transcriptomic responses to each form of injury. Transcriptional changes also showed that paracrine-induced injury to neighboring podocytes was similar to the targeted-injured podocytes and was specific for each podocyte injury model. In silico ligand-receptor analysis of ligands secreted by the insult-targeted podocytes and receptors expressed by the responsive, paracrine-injured counterparts identified 19 candidate mediator pairs that were shared among the three injury models. Several of these were enriched in patients with histological evidence of glomerular injury present in the Nephrotic Syndrome Study Network (NEPTUNE). One-factor-at-a-time candidate approaches validated the ability of these candidate pathways to mediate aspects of the podocyte injury models. Finally, an all-inclusive, comprehensive investigation of this signaling space using a systematic Design-of-Experiment analysis revealed that transforming growth factor-β1 (TGF-β1) signaling is a critical mediator of mitochondrial dysfunction during podocyte injury. Together, these findings define a new concept for future studies to understand the pathways involved in animal models and ultimately human studies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Injury-induced paracrine effects on the podocyte's transcriptome. · full record | OpenQuestion